ScreenerHero

HURATuHURA Biosciences Inc. Common Stock

NAS · US · Healthcare · Biotechnology · tuhurabio.com
2.000USD-12.28%Mkt Cap: 127.45M $P/E: —

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune ago…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap127.45M $
Enterprise Value149.94M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.05M $
Revenue/Share—
Last Price2.000 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.64
PEG—
EV/EBITDA-4.72
EV/Revenue—
P/S—
P/B7.76
EPS (TTM)-0.53
EPS (Forward)-0.61
52W Range
0.410053% of range3.430
52W High3.430 USD
52W Low0.4100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.57%
ROA-109.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.63M $
CapEx (TTM)76.08K $
FCF Margin—
FCF Yield-17.51%
Net Debt8.18M $
Net Debt/EBITDA-0.26
Balance Sheet
Debt/Equity0.03
Current Ratio0.18
Quick Ratio0.11
Book Value/Sh0.2860 USD
Cash/Share0.0160 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:35
Split DateOct 18, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.040 USD
Upside (mean)+302.0%
Target Range6.200 USD – 10.00 USD
$6.200+302.0% to mean$10.00
# Analysts5
Ownership
Shares Out.63.73M
Float39.68M
Insiders34.62%
Institutions14.21%
Short Interest
Short Ratio20.1d
Short % Float13.21%
Short % Out.10.22%
Shares Short6.51M
Short (prev mo.)6.99M
Technical
SMA 502.277 (-12.2%)
SMA 2001.830 (+9.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)297.04K
Avg Vol (10d)354.06K
Technical Indicators
RSI (14)39.7
MACD-0.0067
MACD Signal-0.0102
MACD Hist.+0.0035
BB Upper2.410 USD
BB Middle2.183 USD
BB Lower1.956 USD
BB Width20.81%
ATR (14)0.1760 USD
Vol Ratio (20d)1.44x